• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Perspective Therapeutics Inc.

    11/14/24 6:14:40 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care
    Get the next $CATX alert in real time by email
    SC 13G 1 d11530517_13-g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.)*

     

     

    Perspective Therapeutics, Inc.
    (Name of Issuer)

     

     

    Common Stock, $0.001 par value
    (Title of Class of Securities)

     

     

    46489V302
    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)

     

    [ ] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     
     

     

    CUSIP No. 46489V302    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Partners Management LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      3,590,426  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      3,590,426  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      3,590,426  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.3%1  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

     

    1 The percentage of ownership based on 67,427,667 shares of Common Stock of the Issuer outstanding as of August 7, 2024, as reported on the Issuer’s Form 10-Q filed on August 13, 2024.

     
     

     

    CUSIP No. 46489V302    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Partners Management (GP) LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      3,590,426  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      3,590,426  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      3,590,426  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.3%2  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    2 The percentage of ownership based on 67,427,667 shares of Common Stock of the Issuer outstanding as of August 7, 2024, as reported on the Issuer’s Form 10-Q filed on August 13, 2024.

     
     

     

    CUSIP No. 46489V302    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Capital Partners Fund (GP) LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      3,590,426  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      3,590,426  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      3,590,426  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.3%3  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO, PN

     

    3 The percentage of ownership based on 67,427,667 shares of Common Stock of the Issuer outstanding as of August 7, 2024, as reported on the Issuer’s Form 10-Q filed on August 13, 2024.

     
     

     

    CUSIP No. 46489V302    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Avidity Capital Partners (GP) LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      3,590,426  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      3,590,426  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      3,590,426  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.3%4  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    4 The percentage of ownership based on 67,427,667 shares of Common Stock of the Issuer outstanding as of August 7, 2024, as reported on the Issuer’s Form 10-Q filed on August 13, 2024.

     
     

     

    CUSIP No. 46489V302    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      David Witzke  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      3,590,426  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      3,590,426  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      3,590,426  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.3%5  
         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     


    5 The percentage of ownership based on 67,427,667 shares of Common Stock of the Issuer outstanding as of August 7, 2024, as reported on the Issuer’s Form 10-Q filed on August 13, 2024.

     
     

     

    CUSIP No. 46489V302  

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Michael Gregory  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      3,590,426  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      3,590,426  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      3,590,426  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.3%6  
         

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     


    6 The percentage of ownership based on 67,427,667 shares of Common Stock of the Issuer outstanding as of August 7, 2024, as reported on the Issuer’s Form 10-Q filed on August 13, 2024.

     
     

     

     

    Item 1. (a). Name of Issuer:  
           
        Perspective Therapeutics, Inc.  

     

      (b). Address of issuer's principal executive offices:  
           
       

    2401 Elliott Avenue, Suite 320

    Seattle, Washington 98121

     

     

    Item 2. (a). Name of person filing:  
           
       

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

    David Witzke

    Michael Gregory

     

     

      (b). Address or principal business office or, if none, residence:  
           
       

    Avidity Partners Management LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Partners Management (GP) LLC

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Capital Partners Fund (GP) LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Avidity Capital Partners (GP) LLC

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    David Witzke

    c/o Avidity Partners Management LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

    Michael Gregory

    c/o Avidity Partners Management LP

    2828 N Harwood Street, Suite 1220

    Dallas, Texas 75201

    United States of America

     

     

     

     
     

     

     

      (c). Citizenship:  
           
       

    Avidity Partners Management LP – Delaware

    Avidity Partners Management (GP) LLC – Delaware

    Avidity Capital Partners Fund (GP) LP – Delaware

    Avidity Capital Partners (GP) LLC – Delaware

    David Witzke – United States of America

    Michael Gregory – United States of America

     

     

      (d).   Title of class of securities:  
           
        Common Stock, $0.001 par value  

     

      (e). CUSIP No.:  
           
        46489V302  

     

    Item 3.   If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

      (b) [_] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

      (c) [_] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

      (d) [_] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

      (e)  [X] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) [_] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j)   [_] A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

      (k)   [_] Group, in accordance with §240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     
     

     

     

     
    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:
         
       

    Avidity Partners Management LP: 3,590,426

    Avidity Partners Management (GP) LLC: 3,590,426

    Avidity Capital Partners Fund (GP) LP: 3,590,426

    Avidity Capital Partners (GP) LLC: 3,590,426

    David Witzke: 3,590,426

    Michael Gregory: 3,590,426

     

      (b) Percent of class:
         
       

    Avidity Partners Management LP: 5.3%

    Avidity Partners Management (GP) LLC: 5.3%

    Avidity Capital Partners Fund (GP) LP: 5.3%

    Avidity Capital Partners (GP) LLC: 5.3%

    David Witzke: 5.3%

    Michael Gregory: 5.3%

     

      (c) Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote

    Avidity Partners Management LP: 0

    Avidity Partners Management (GP) LLC: 0

    Avidity Capital Partners Fund (GP) LP: 0

    Avidity Capital Partners (GP) LLC: 0

    David Witzke: 0

    Michael Gregory: 0

     

     

             
        (ii)   Shared power to vote or to direct the vote

    Avidity Partners Management LP: 3,590,426

    Avidity Partners Management (GP) LLC: 3,590,426

    Avidity Capital Partners Fund (GP) LP: 3,590,426

    Avidity Capital Partners (GP) LLC: 3,590,426

    David Witzke: 3,590,426

    Michael Gregory: 3,590,426

     
             
        (iii) Sole power to dispose or to direct the disposition of

    Avidity Partners Management LP: 0

    Avidity Partners Management (GP) LLC: 0

    Avidity Capital Partners Fund (GP) LP: 0

    Avidity Capital Partners (GP) LLC: 0

    David Witzke: 0

    Michael Gregory: 0

     

     

             
        (iv)   Shared power to dispose or to direct the disposition of

    Avidity Partners Management LP: 3,590,426

    Avidity Partners Management (GP) LLC: 3,590,426

    Avidity Capital Partners Fund (GP) LP: 3,590,426

    Avidity Capital Partners (GP) LLC: 3,590,426

    David Witzke: 3,590,426

    Michael Gregory: 3,590,426

     

     

             

     

     
     

     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [__].
       
      N/A
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      N/A
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      N/A
       
       
    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
       

     

     

     

     

     

     

     

     

     

     

     

     

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

     

     

    November 14, 2024

      (Date)
       
     

    David Witzke

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

     

      By: /s/ David Witzke
      David Witzke, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP)
       
     

    Michael Gregory

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

     

      By: /s/Michael Gregory
      Michael Gregory, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP)

     

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

     

    Exhibit 1

    JOINT FILING AGREEMENT

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.001 par value of Perspective Therapeutics, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing

     The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

    IN WITNESS WHEREOF, the undersigned hereby execute this Agreement as of November 14, 2024.

           
     

    David Witzke

    Avidity Partners Management LP

    Avidity Partners Management (GP) LLC

    Avidity Capital Partners Fund (GP) LP

    Avidity Capital Partners (GP) LLC

     

    /s/ David Witzke 

      David Witzke, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP)
         
      Michael Gregory
      Avidity Partners Management LP
      Avidity Partners Management (GP) LLC
      Avidity Capital Partners Fund (GP) LP
      Avidity Capital Partners (GP) LLC
         
      By: /s/ Michael Gregory 
      Michael Gregory, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP)

     

     

     

     

    Get the next $CATX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CATX

    DatePrice TargetRatingAnalyst
    3/13/2025$10.00Buy
    H.C. Wainwright
    3/7/2025$15.00Sector Outperform
    Scotiabank
    11/25/2024$24.00 → $5.00Buy → Neutral
    BofA Securities
    10/24/2024$20.00Buy
    UBS
    10/1/2024$25.00Outperform
    Wedbush
    9/25/2024$21.00Buy
    Truist
    7/25/2024$24.00Buy
    BofA Securities
    5/9/2024Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CATX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Spoor Johan M. bought $59,673 worth of shares (26,676 units at $2.24), increasing direct ownership by 59% to 59,383 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 6:44:41 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Director Williamson Robert F Iii bought $132,151 worth of shares (60,337 units at $2.19), increasing direct ownership by 124% to 108,982 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 5:04:49 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Graham Juan bought $74,946 worth of shares (33,333 units at $2.25), increasing direct ownership by 1,649% to 35,354 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 5:03:59 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Financials

    Live finance-specific insights

    See more
    • Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

        Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [212Pb]VMT-α-NET[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested Three of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. First responses for two patients occurred after end of treatment period and are subject to confirmation, in addition to the previously reported patient with confirmed response who remains in response The five other patients in Coh

      1/24/25 7:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025

      SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that an abstract on updated interim results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET (NCT05636618) has been accepted as a poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) taking place on January 23-25, 2025 in San Francisco, CA. The poster presentation entitled "Interim Safety and Efficacy data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs)" will

      1/22/25 7:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

      SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 21-23, 2024 in Chicago. The presentation entitled "Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)" will be p

      11/15/24 4:08:05 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

      First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our clinical stage potential new medicines based on our next generation targeted radiopharmaceutical technology platformEnrollment ongoing for VMT-α-NET, a next generation SSTR2-targeting potential new medicine, with 40 patients enrolled through end of April 2025 in Cohort 2 of the Phase 1/2a trial in neuroendocrine tumorsEnrollment ongoing for VMT01, a first-in-class MC1R targeting potential new medicine, with first patient treated at a new monotherapy dose level in April 2025, following the first patient

      5/12/25 4:36:46 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics to Participate in Upcoming May Investor Conferences

      SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate and be available for one-on-one meetings with investors at the following upcoming investor conferences. Bank of America Global Healthcare ConferenceDate: Tuesday, May 13, 2025Format: Fireside ChatTime: 11:35 a.m. – 11:50 a.m. PT / 2:35 p.m. – 2:50 p.m. ETLocation: Las Vegas, NV 2025 RBC Capital Markets Global Healthcare Conference Date: Tuesday, May 20, 2025Format: Fireside ChatTime: 3:05 p.m. - 3:30 p.m

      5/1/25 7:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

      SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first patient was treated with [212Pb]PSV359 in a Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha (FAP-α). Patients are being selected for [212Pb]PSV359 targeted alpha particle therapy by SPECT imaging with [203Pb]PSV359. "We are excited to explore a new avenue to treat cancers expressing FAP-α wi

      4/29/25 7:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Perspective Therapeutics Inc.

      SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

      11/14/24 6:14:40 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

      SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

      11/14/24 4:05:13 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

      SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

      11/7/24 9:24:55 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    SEC Filings

    See more
    • SEC Form SD filed by Perspective Therapeutics Inc.

      SD - Perspective Therapeutics, Inc. (0000728387) (Filer)

      5/19/25 5:02:08 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Perspective Therapeutics Inc.

      10-Q - Perspective Therapeutics, Inc. (0000728387) (Filer)

      5/12/25 4:34:55 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

      5/12/25 4:30:53 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Perspective Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $10.00

      3/13/25 7:26:51 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Scotiabank initiated coverage on Perspective Therapeutics with a new price target

      Scotiabank initiated coverage of Perspective Therapeutics with a rating of Sector Outperform and set a new price target of $15.00

      3/7/25 8:03:16 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Perspective Therapeutics from Buy to Neutral and set a new price target of $5.00 from $24.00 previously

      11/25/24 7:39:30 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Spoor Johan M. bought $59,673 worth of shares (26,676 units at $2.24), increasing direct ownership by 59% to 59,383 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 6:44:41 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Director Williamson Robert F Iii bought $132,151 worth of shares (60,337 units at $2.19), increasing direct ownership by 124% to 108,982 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 5:04:49 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Graham Juan bought $74,946 worth of shares (33,333 units at $2.25), increasing direct ownership by 1,649% to 35,354 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 5:03:59 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Leadership Updates

    Live Leadership Updates

    See more
    • Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

      SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the appointment of Juan Graham as the Company's Chief Financial Officer (CFO), effective as of January 6, 2025. In connection with the transition, Jonathan Hunt will no longer serve as CFO but will continue serving as the Company's Chief Accounting Officer (CAO). "In less than 18 months, Perspective has delivered initial clinical data for two new potential medicines based on its next generation targeted radiopharmaceutical technology platform,

      1/6/25 8:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

      SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to an updated list of additions to the membership list, considered to be final, as of Monday, June 10th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total mark

      6/12/24 7:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

      Phase I/2a clinical trials initiated: VMT-α-NET for neuroendocrine tumors, and VMT01 for melanoma. Preliminary results from initial cohorts expected by end of 2023.First patient dosed in Phase 1/2a dose escalation trial of VMT01 for treatment of MC1R-positive metastatic melanoma. RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports second quarter financial results for the period end

      8/11/23 8:00:30 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care